The Famous, Fearsome Archaeopteryx Was More Bird Than We Knew
It's been more than 160 years since Archaeopteryx first shook up science as the missing link—part reptile, part bird—and indicated that today's pigeons and parakeets are the feathery descendants of dinosaurs.
But despite decades of research, there's still more to learn. Case in point: a newly described fossil, nicknamed the Chicago Archaeopteryx, may be the most detailed and revealing specimen yet.
'The most important findings all center around rarely preserved soft tissues. For the first time we see the soft tissue of the hand and foot,' said Jingmai O'Connor, lead author of the new study in Nature and associate curator of fossil reptiles at the Field Museum, in an email to Gizmodo.
With that information, paleontologists are getting a more nuanced understanding of the creature than they've ever had.
'The tissue on the right hand suggests that the two main digits of the hand were not bound together in soft tissue and that the third digit could move independently, supporting long abandoned claims from the 90s that Archaeopteryx could use its hands to climb,' O'Connor added.
The fossil had been in private hands since 1990, but made its public debut at Chicago's Field Museum last year. At roughly the size of a pigeon, the Chicago Archaeopteryx is the smallest specimen yet found, and was pulled from the same German limestone where all Archaeopteryx fossils come from.
What sets this fossil apart is its pristine preservation and exhaustive preparation. Over a year of painstaking work by the Field's fossil prep team, led by the museum's chief preparator Akiko Shinya, revealed bones and soft tissues that had never been visible before. That tissue included a set of upper wing feathers called tertials, which may have helped Archaeopteryx fly when many of its dinosaur cousins couldn't.
The team used UV light and CT scans to carefully chip away the rock encasing the bird's mineralized remains, sometimes removing just fractions of a millimeter to avoid damaging tissue. The result is the most complete and delicately preserved Archaeopteryx yet.
Among the findings: scales on the bottom of the animal's toes, soft tissue in the fingers, and fine details in the skull that could help explain how modern birds evolved flexible beaks. But the key takeaway in this paper is evidence of the creature's flight. While earlier dinosaurs had feathers and wings, Archaeopteryx may have been the first to actually take wing, based on the tertials, which are missing in feathered dinosaurs that aren't quite birds.
Though non-avian dinosaurs couldn't fly, this spunky critter could. That supports the idea that flight evolved more than once in dinosaurs—an exceptionally cool notion that serves as a reminder that Archaeopteryx is merely one branch of the tree of life—albeit a very neat one.
And as for this fossil, O'Connor says we're only just scratching the surface. More analysis of the Chicago Archaeopteryx will reveal more details of how these flying dinosaurs lived.
'Some very cool and surprisingly bird-like new features of the skull; chemical data about the soft tissues; the full body CT scan, and much, much more are still to come,' O'Connor added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Moon phase today: What the moon will look like on July 7, 2025
Ever wonder why the moon looks different every night? Well, that's because of a thing called the lunar cycle. This is a recurring series of eight unique phases of the moon's visibility. The whole cycle takes about 29.5 days (according to NASA), and these different phases happen as the Sun lights up different parts of the moon whilst it orbits Earth. The moon is always there, but what we see on Earth changes depending on how much it is lit up. See what's happening with the moon tonight, July 6. What is today's moon phase? As of Monday, July 7, the moon phase is Waxing Gibbous. From Earth, 89% of the moon will appear visible (according to NASA's Daily Moon Observation). This is the 12th day of the lunar cycle, and the moon is so close to being full. Some of the most notable things to spot with your bare eye tonight are the Aristarchus Plateau, the Mare Serenitatis, and the Mare Tranquillitatis. With binoculars, you'll also be able to catch a glimpse of the Posidonius Crater, the Alphonsus Crater, and the Clavius Crater. Add a telescope and you'll also spot Apollo 17, Fra Mauro Highlands, and Caucasus Mountains. When is the next full moon? This month's full moon will take place on July 10. The last full moon was on June 11. What are moon phases? Moon phases are caused by the 29.5-day cycle of the moon's orbit, which changes the angles between the Sun, Moon, and Earth. Moon phases are how the moon looks from Earth as it goes around us. We always see the same side of the moon, but how much of it is lit up by the Sun changes depending on where it is in its orbit. This is how we get full moons, half moons, and moons that appear completely invisible. There are eight main moon phases, and they follow a repeating cycle: New Moon - The moon is between Earth and the sun, so the side we see is dark (in other words, it's invisible to the eye). Waxing Crescent - A small sliver of light appears on the right side (Northern Hemisphere). First Quarter - Half of the moon is lit on the right side. It looks like a half-moon. Waxing Gibbous - More than half is lit up, but it's not quite full yet. Full Moon - The whole face of the moon is illuminated and fully visible. Waning Gibbous - The moon starts losing light on the right side. Last Quarter (or Third Quarter) - Another half-moon, but now the left side is lit. Waning Crescent - A thin sliver of light remains on the left side before going dark again.
Gizmodo
an hour ago
- Gizmodo
An AI That Promises to 'Solve All Diseases' Is About to Test Its First Human Drugs
Deep inside Alphabet, the parent company of Google, a secretive lab is working on a promise so audacious it sounds like science fiction: to 'solve all diseases.' The company, Isomorphic Labs, is now preparing to start its first human clinical trials for cancer drugs designed entirely by artificial intelligence. In a recent interview with Fortune, Colin Murdoch, President of Isomorphic Labs and Chief Business Officer of Google DeepMind, confirmed the company is on the verge of this monumental step. For anyone who has watched a loved one battle a devastating illness, the hope this offers is immense. But for a public increasingly wary of AI's power, it raises a chilling question: can we really trust a 'black box' algorithm with our lives? Isomorphic Labs was born from DeepMind's celebrated AlphaFold breakthrough, the AI system that stunned scientists by predicting the complex 3D shapes of proteins. To understand why this is a big deal, you need to know how drugs are traditionally made. For decades, it's been a slow, brutal process of trial and error. Scientists spend an average of 10 to 15 years and over a billion dollars to bring a single new drug to market, with most candidates failing along the way. Isomorphic Labs uses its AI, AlphaFold 3, to radically accelerate this. The AI can predict the complex 3D structures of proteins in the human body with stunning accuracy, allowing scientists to digitally design new drug molecules that are perfectly shaped to fight a specific disease, all before ever entering a physical lab The company has already signed multi-billion dollar deals with pharmaceutical giants Novartis and Eli Lilly, and just raised $600 million in new funding to move its own drug candidates—starting with oncology—into human trials. The promise is a medical utopia. 'This funding will further turbocharge the development of our next-generation AI drug design engine, help us advance our own programs into clinical development, and is a significant step forward towards our mission of one day solving all disease with the help of AI,' CEO Sir Demi Hassabis, who won the 2024 Nobel Laureate in Chemistry for his pioneering work on AlphaFold 2, said back in March. But when Big Tech starts designing medicine, who owns your cure? This is where deep-seated fears about AI's role in our lives come into focus. The biggest concern is the 'black box' problem: we know the AI gives an answer, but we don't always know how. This raises critical questions: When contacted by Gizmodo, a spokesperson for Isomorphic Labs said the company 'don't have anything more to share.' AI could revolutionize medicine. But if left unchecked, it could also replicate the worst parts of the tech industry: opacity, monopoly, and profit over access. Isomorphic Labs is pushing humanity toward a monumental turning point. If they succeed, they could alleviate more suffering than any other invention in history. But to do so, they first have to convince a skeptical public that the promise is worth the unprecedented risk.
Yahoo
2 hours ago
- Yahoo
Women are twice as likely to suffer from Alzheimer's as men. Scientists have figured out why
Experts have long known that women are at a greater risk of developing Alzheimer's disease. They're twice as likely to be affected as men. Now scientists say they may be on their way to understanding why that's the case - pinpointing two stark differences between men and women. Firstly, women have different chromosomes than men. They also undergo menopause: a process that occurs when a woman's reproductive hormones naturally decline starting in her 40s and 50s. One in three older Americans dies with Alzheimer's, or another dementia, according to the Alzheimer's Association. Almost two-thirds of Americans with Alzheimer's disease are women. 'Epidemiologically, we see that for almost all neurological diseases, there are differences in how many biological women and men are affected,' Anna Bonkhoff, resident and research fellow in neurology at Harvard Medical School and Mass General Brigham, explained in a recent interview. 'There's a tendency, for example, in [multiple sclerosis] and migraine for more females to be affected, while it's the contrary for brain tumors and Parkinson's.' 'Just based on these numbers, you get the feeling that something needs to underlie these differences in terms of the biology,' she added. Looking inside the body, while women have two 'X' chromosomes, men have an 'X' and a 'Y.' Chromosomes are thread-like structures of DNA inside our cells that carry hundreds or even thousands of genes. Genes determine a person's physical characteristics. Differences between genes held on the X and Y chromosomes may give women an increased chance of developing Alzheimer's disease. Recent research has shown that genes on the X chromosome are related to Alzheimer's disease, including that women with Alzheimer's live longer than men with the disease due to their second X chromosome. 'A lot of genes for the immune system and regulating brain structure are located on the X chromosome, so the dosages differ to certain degrees between men and women. That seems to have an effect,' said Bonkhoff. Women's different dominant hormones — such as estrogen, which acts on the brain — could also play a role. 'Menopause is part of the puzzle, probably one of the bigger ones,' Bonkhoff said. 'I'm not saying it's the only one — aging is relevant by itself, and there's a lot of interesting research looking at what aging does to the immune system that seems to have implications for cognitive changes.' During menopause, when ovaries stop producing estrogen and progesterone, some women turn to hormone replacement therapy. The practice offers relief for symptoms of lower hormone levels in menopause such as hot flashes. But for some women it may increase their risk of dangerous medical conditions, including heart attacks, strokes, breast cancer, blood clots and gall bladder disease, according to the Centers for Disease Control and Prevention. Women who received hormone replacement after age 70 also have significantly higher levels of the protein known as 'tau,' according to Rachel Buckley, associate professor of neurology at Harvard Medical School. The accumulation of tau is a hallmark of Alzheimer's disease. They also suffered higher cognitive decline. Buckley published those findings last March in the journal Science Advances. But further research is needed to understand these associations. 'We work with a lot of secondary data that already exists, and that's great but there are limitations to what we can do with it,' Buckley said. 'We're trying to see if we can set up a new study design where we can really look at the time of menopause, what is changing in the blood, what is changing in the brain, what is changing in cognition, and how that might be associated with later life risk.'
